2017-05-18 07:15 Xbrane Biopharma releases interim report for the period January - March 2017 Xbrane Biopharma ABs interim report for the period January – March 2017 is now available on the Company’s […]
2017-05-15 13:15 Episurf Medical continues its communication with the US Food and Drug Administration (FDA) regarding appropriate route for market acceptance in the US In July 2016, Episurf Medical participated in a pre-submission meeting with the FDA in Washington. Following this meeting, […]
2017-05-15 09:21 Episurf Medical Interim Report 1 January – 31 March, 2017 First quarter compared to 2016, Group » Group net sales increased by 12% to SEK 462,979 (411,834). » […]
2017-05-11 08:17 Episurf Medical reaches milestone of 200 implants Episurf Medical announces that the 200th implantation of the Episealer knee implant has been scheduled for the coming […]
2017-05-10 08:15 OrganoClick AB (publ) publishes its interim report for Q1 2017 “After the first four months of the year I can conclude that we are on the right path. […]
2017-05-09 21:00 OrganoClick AB publishes its annual report for 2016 OrganoClick has during the year had a continuous good organic sales growth of 28 % to a net […]
2017-05-08 08:38 Episurf Medical obtains further granted patent in the US Episurf Medical has received another Notice of Allowance from the United States Patent and Trademark Office (USPTO). The […]
2017-05-04 07:13 Xbrane Biopharma recruits CFO and Head of Investor Relations Xbrane Biopharma has recruited Susanna Helgesen as CFO and Head of Investor Relations at Xbrane. Susanna has previously […]
2017-04-28 15:10 Diamorph publishes Annual Report 2016 As of April 28, 2017 at 08.00, the company’s annual report for 2016 is available on diamorph.com/investor-relations . […]
2017-04-28 07:56 Xbrane Biopharma publishes 2016 annual report Xbrane Biopharma ABs annual report for 2016 is now available at the comapnys website, www.xbrane.com. The annual report […]
2017-04-26 15:42 OrganoClicks subsidiary BIOkleen Miljökemi AB signs general agreement with Ahlsell OrganoClicks subsidiary BIOkleen Miljökemi AB signs general agreement with Ahlsell for distribution of BIOkleen’s products for house and […]
2017-04-20 09:50 Notice of Annual General Meeting in Diamorph AB (publ) Notice of Annual General Meeting in Diamorph AB (publ), reg. No. 556647-5371, is available on the company’s website, […]
2017-04-20 09:40 Episurf Medical publish annual report, summon to the annual general meeting and bring forward its reporting date for O1 2017 Episurf Medical’s annual report for 2016 is available as of today at the company’s website, www.episurf.com. Read more […]
2017-04-11 15:20 IRRAS Appoints Medical Technology Leader C. Lance Boling as Vice President, Product Development IRRAS, a commercial-stage medical technology company developing breakthrough devices for a broad range of brain pathology therapeutic applications […]
2017-04-11 08:51 Xbrane Biopharma reports positive in-vivo efficacy data on Spherotide Xbrane Biopharma has, in preparation for upcoming clinical trials, done a comparative study in minipigs on the 1 […]
2017-04-10 11:10 Changes in Episurf Medical AB’s management group Episurf Medical strengthens the company’s management group which will consist of the following members with their respective responsibilities: […]
2017-04-06 09:30 Episurf Medical obtains further granted patent in Australia The Australian patent office IP Australia has announced that Episurf Medical has obtained another granted patent in Australia. […]
2017-04-03 13:51 Episurf Medical AB to present at Aktiespararna’s börskväll, held in Stockholm on april 20 Episurf Medical AB will present at Aktiespararna’s Börskväll, an investor conference held in Stockholm (Hotel Rival) on April […]
2017-04-03 13:49 Episurf Medical’s 50th Episealer® implant in Germany demonstrates rapid clinical adoption Episurf Medical announces that the 50th implantation in Germany of the Episealer® knee implant will take place in […]
2017-03-31 12:38 Change in number of shares and votes in Episurf Medical AB Episurf Medical AB has, in accordance with information previously announced, conducted a new issue of shares with preferential […]
2017-03-27 08:53 Xbrane Biopharma delivers first batch of Spherotide to a value of 7 MSEK Xbrane Biopharma has delivered its first batch of Spherotide to its partner in the Middle East to a […]
2017-03-24 16:18 OrganoClicks subsidiary BIOkleen signs general agreement with Granngården OrganoClicks subsidiary, BIOkleen Miljökemi AB, sells and markets cleaning and maintenance products for wood, home, house, and automotive. […]
2017-03-16 09:26 Outcome of Episurf Medical’s rights issue The subscription period for Episurf Medical’s new issue of A and B shares with preferential right for the […]
2017-03-02 16:08 Episurf Medical AB to present at Aktiedagen, held in Stockholm on March 6 Episurf Medical AB will present at Aktiedagen, an investor conference held in Stockholm (Operaterassen, Karl XII:s torg) on […]
2017-02-27 07:49 Xbrane Biopharma releases 2016 Year End Report Xbrane Biopharma ABs Year End Report for 2016 is now available on the Company’s website, www.xbrane.com. October – […]
2017-02-27 07:43 Xbrane Biopharma reports positive in-vitro biosimilarity data on Xlucane Xbrane Biopharma has performed a comprehensive in-vitro biosimilarity study with several pilot scale R&D batches of Xlucane versus […]
2017-02-22 12:55 OrganoClick AB (publ) publish Year end report 2016 The fourth quarter was a strong end to the year, with organic sales growth for the group of […]
2017-02-21 08:01 Summary from extraordinary general meeting of Episurf Medical AB (publ) Episurf Medical AB (publ) held an extraordinary general meeting on 20 February 2017 at which it was resolved, […]
2017-02-20 09:43 Episurf Medical Year-end Report 2016 Fourth quarter 2016 compared to 2015, Group » Group net sales increased by 168% to SEK 1,007,759 (375,368). […]
2017-02-17 15:14 Episurf Medical’s 3D-based damage assessment tool: positive development in US patenting Episurf Medical pursues patent applications (not yet published) within the area of 3D-based assessment of joint lesions. In […]
